Male contraception

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 2, 2002, Pages 193-203

  Wang, Christina ^a,b   Swerdloff, Ronald S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c Division of Endocrinology

Author keywords

Androgens; Gonadotropin suppressing agents; Hormonal male contraception

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; ESTRADIOL; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSSYPOL; LEVONORGESTREL; NORETHISTERONE ENANTATE; PROGESTERONE RECEPTOR MODULATOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; ANDROGEN RECEPTOR; ANTIANDROGEN; ESTROGEN; MALE CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

AZOOSPERMIA; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONDOM; CONTRACEPTION; DRUG EFFICACY; EPIDIDYMIS; ETHNIC DIFFERENCE; FAMILY PLANNING; HORMONAL CONTRACEPTION; HUMAN; LIPID METABOLISM; NONHUMAN; OLIGOSPERMIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SPERMATOGENESIS; TESTIS; TREATMENT FAILURE; VAS DEFERENS; WORLD HEALTH ORGANIZATION; DRUG EFFECT; GENETICS; MALE; METABOLISM; METHODOLOGY; UTILIZATION REVIEW; VASECTOMY;

ANDROGEN ANTAGONISTS; ANDROGENS; CONDOMS; CONTRACEPTION; CONTRACEPTIVE AGENTS, MALE; CONTRACEPTIVES, ORAL, COMBINED; ESTROGENS; HUMANS; MALE; PROGESTINS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; SPERMATOGENESIS; VASECTOMY;

EID: 0036526720     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2001.0270     Document Type: Article

References (49)

1. Trussel J & Kost K. Contraceptive failure in the United States: A critical review of literature. Studies in Family Planning 1987; 18: 237-283.
2. Li S, Goldstein M, Zhu J & Huber D. The no-scalpel vasectomy. Journal of Urology 1991; 145: 341-344.
3. Li S. Percutaneous injection of vas deferens. Chinese Journal of Urology 1980; 1: 193-198.
4. Chen ZW, Gu YQ, Liang XW et al. Safety and efficacy of percutaneous injection of polyurethane elastomer (MPU) plugs for vas occlusion in man. International Journal of Andrology 1992; 15: 468-472.
5. Patanelli DJ (ed). Hormonal control of male fertility. Bethesda: US DHEW Publication No. (NIH) 78-1097, 1978.
6. Cunningham GR, Silverman VE & Kohler DO. Clinical evaluation of testosterone enanthate for induction and maintenance of reversible azoospermia in man. In Patanelli DJ (ed.) Hormonal Control of Male Fertility, pp 71-92. DHEW Publication (NIH) 78-1097, 1978.
7. Swerdloff RS, Palacios A, McClure RD et al. Clinical evaluation of testosterone enanthate in the reversible suppression of spermatogenesis in the human male: efficacy, mechanism of action, and adverse effects. In Patanelli DJ (ed.) Hormonal control of male fertility, pp 41-70. Bethesda: US DHEW (NIH), 1978.
8. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990; 336: 955-959.
9. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertility and Sterility 1996; 65: 821-829.
10. Handelsman DJ, Conway AJ & Boylan LM. Suppression of human spermatogenesis by testosterone implants in man. Journal of Clinical Endocrinology and Metabolism 1992; 75: 1326-1332.
11. Behre HM, Baus S, Kliesch S et al. Potential of testosterone buciclate for male contraception: endocrine differences between responders and non-responders. Journal of Clinical Endocrinology and Metabolism 1995; 80: 2394-2403.
12. Zhang CY, Gu YQ, Wang XH et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Journal of Andrology 1998; 19: 761-768.
13. Behre HM, Abshagen K, Oettel M et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. European Journal of Endocrinology 1999; 140: 414-419.
14. Zhang GY, Gu YG, Wang XH et al. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3642-3647.
15. Kamischke A, Plöger D, Venherm S et al. Intramuscular testosterone undecanoate with or without oral levornogestrel: a randomized placebo controlled clinical trial for male contraception. Clinical Endocrinology (Oxford) 2000; 53: 351-358.
16. st century. In Wang C (ed.) Male Reproductive Function, pp 303-319. Boston: Kluwer Academic Publisher, 1999.
17. Wang C & Swerdloff RS. Androgen replacement therapy, risks and benefits. In Wang C (ed.) Male Reproductive Function, pp 157-172. Boston: Kluwer Academic Publisher, 1999.
18. Handelsman DJ. The safety androgens: prostate and cardiovascular disease. In Wang C (ed.) Male Reproductive Function, pp 173-189. Boston: Kluwer Academic Publisher, 1999.
19. Schearer SB, Alvarez-Sanchez F, Anselmo J et al. Hormonal contraception for men. International Journal of Andrology 1978; Suppl 2: 680-712.
20. Bebb RA, Anawalt BD, Christiansen RB et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: A promising male contraceptive approach. Journal of Clinical Endocrinology and Metabolism 1996; 81: 757-762.
21. Anawalt BD, Bebb RA, Bremner WH & Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotrophin levels with fewer metabolic effects than higher dosage combinations. Journal of Andrology 1999; 20: 407-414.
22. World Health Organization Task Force on Methods for the Regulation of Male Fertility Comparison of two androgens plus depo-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertility and Sterility 1993; 60: 1062-1068.
23. Wu FC, Balasubramanian R, Mulders TM & Coelingh-Bennink HJ. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. Journal of Endocrinology and Metabolism 1999; 84: 112-122.
24. Anawalt BD, Herbst BD, Herbst KL et al. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high density lipo protein suppression. Fertility and Sterility 2000; 14: 704-714.
25. Meriggiola MC, Bremner WJ, Paulsen CA et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially high effective male contraceptive. Journal of Clinical Endocrinology and Metabolism 1996; 81: 3018-3023.
26. Meriggiola MC, Bremner WJ, Constantino A et al. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Human Reproduction 1998; 13: 1225-1229.
27. Kamischke A, Venherm S, Plöger D et al. Intramuscular testosterone undecanoate and nonethisterone enanthate in a clinical trial for male contraception. Journal of Clinical Endocrinology and Metabolism 2000; 86: 303-309.
28. Handelsman DI, Conway AJ, Howe CJ et al. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. Journal of Clinical Endocrinology and Metabolism 1996; 81: 4113-4121.
29. Büchter D, von Eckardstein S, von Eckardstein A et al. Clinical trial of transdermal testosterone and oral levonogestrel for male contraception. Journal of Clinical Endocrinology and Metabolism 1999; 84: 1244-1249.
30. Wang C & Yeung KK. Use of low-dosage cyprosterone acetate as a male contraceptive. Contraception 1980; 21: 245-272.
31. Hamann LG, Higuchi RI, Zhi L et al. Syntheses and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono [5,6-g] quinolines. Journal of Medicinal Chemistry 1998; 41: 623-639.
32. Kumar N, Didolkar AK, Monder C et al. The biological activity of 7 α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992; 130: 3677-3683.
33. Anderson RA, Martin CW, Kung AWC et al. 7α-Methyl-19- northestosterone maintains sexual behavior and mood in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3556-3562.
34. Bhasin S, Heber D, Steiner BS et al. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist and androgen. Journal of Clinical Endocrinology and Metabolism 1985a; 60: 998-1003.
35. Bhasin S, Heber D, Steiner B et al. Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist. Clinical Endocrinology 1984; 20: 119-128.
36. Behre HM, Nashan D, Hubert W & Nieschlag E. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. Journal of Clinical Endocrinology and Metabolism 1992; 74: 84-90.
37. Pavlou SN, Wakefield GB, Island DP et al. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men. Journal of Clinical Endocrinology and Metabolism 1987; 64: 931-936.
38. Tom L, Bhasin S, Salameh W et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. Journal of Clinical Endocrinology and Metabolism 1992; 75: 476-483.
39. Bagatell CJ, Matsumoto AM, Christensen RB et al. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. Journal of Clinical Endocrinology and Metabolism 1993; 77: 427-432.
40. Behre HM, Klein B, Steinmeyer E et al. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. Journal of Clinical Endocrinology and Metabolism 1992; 75: 393-398.
41. Swerdloff RS, Bagatell CJ, Wang C et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate is maintained by testosterone enanthate alone. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3527-3533.
42. Ewing L. Effects of testosterone and estradiol, silastic implants, on spermatogenesis in rats and monkeys. In Patanelli DJ (ed.) Hormonal Control of Male Fertility, pp 173-194. Bethesda: US DHEW Publication No. (NIH) 78-1097, 1978.
43. Anderson RA, Wallace AM & Wu FCW. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I. Higher 5α reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. Journal of Clinical Endocrinology and Metabolism 1996; 81: 902-908.
44. Wang C, Berman NG, Veldhuis JD et al. Graded testosterone infusions distinguish gonadotropin negative feedback responsiveness in Asian and White men - A clinical research center study. Journal of Clinical Endocrinology and Metabolism 1998; 83: 870-876.
45. Santner SJ, Albertson B, Zhang G-Y et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. Journal of Clinical Endocrinology and Metabolism 1998; 83: 2104-2109.
46. Johnson L, Barnard JJ, Rodriguez L et al. Ethnic difference in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives. Journal of Andrology 1998; 19: 348-357.
47. Sinha-Hikim A, Wang C, Lue YH et al. Spontaneous germ cell apoptosis in humans: evidence for ethnic differences in the susceptability of germ cells to programmed cell death. Journal of Clinical Endocrinology and Metabolism 1998; 83: 152-156.
48. Waites GMH, Wang C & Griffin PD. Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. International Journal of Andrology 1998; 21: 8-12.
49. Handelsman DJ, Wishasts, Conway AJ. Oestradiol enhances testosterone-induced suppression of human spermatogenesis. Human Reproduction 2000; 15: 672-679.